title: Adolescent depression: controlled desipramine treatment and atypical features.
abstract: The study was designed to test the efficacy of desipramine in adolescents with major depression (MDD). In addition, we assessed the presence of atypical features of MDD, consisting of mood reactivity and two of four associated features (rejection sensitivity, hyperphagia, hypersomnia, and leaden paralysis). Patients were randomized to desipramine (DMI) or placebo for 6 weeks, provided they failed to improve (e.g., meeting MDD criteria and a Hamilton Depression Scale score > or = 18) after 2 weeks on single blind placebo. Of 94 adolescents (ages 13-18) who were diagnosed as having MDD, 64 entered the study and 62 received placebo for 2 weeks. Of these, 45 were randomized to DMI or placebo. Completed analyses did not reveal significant improvement for the active treatment compared to the placebo. A large proportion of adolescents responded to placebo (50%), suggesting the need for very large samples to detect differential treatment efficacy, should it exist. A relatively high rate of atypical depression was observed (47% in the 64 patients entered). In view of the demonstrated specificity of monoamine oxidase inhibitor efficacy in adults with atypical features of MDD, this clinical subtype may have relevance to future investigation of therapeutic interventions in adolescent MDD.
authors.affiliation: New York State Psychiatric Institute, New York 10032, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: Klein
authors.forename: S
authors.initials: S
authors.lastname: Mannuzza
authors.forename: H S
authors.initials: HS
authors.lastname: Koplewicz
authors.forename: N K
authors.initials: NK
authors.lastname: Tancer
authors.forename: M
authors.initials: M
authors.lastname: Shah
authors.forename: V
authors.initials: V
authors.lastname: Liang
authors.forename: M
authors.initials: M
authors.lastname: Davies
mesh_terms: D000293:Adolescent; D000342:Affective Symptoms / Q000145:classification*; D000704:Analysis of Variance; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002648:Child; D003866:Depressive Disorder / Q000145:classification / Q000188:drug therapy*; D003891:Desipramine / Q000627:therapeutic use*; D018450:Disease Progression; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D016037:Single-Blind Method; D009626:Terminology as Topic; D016896:Treatment Outcome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D003891:Desipramine